Dr. Reddy's Laboratories (RDY) Competitors $13.82 +0.22 (+1.58%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$13.80 -0.01 (-0.07%) As of 08/8/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. TAK, ARGX, ONC, BNTX, INSM, SMMT, TEVA, GMAB, QGEN, and MRNAShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Qiagen (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Qiagen Moderna Dr. Reddy's Laboratories (NYSE:RDY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation. Is RDY or TAK a better dividend stock? Dr. Reddy's Laboratories pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.8%. Dr. Reddy's Laboratories pays out 10.6% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 183.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Is RDY or TAK more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Takeda Pharmaceutical's net margin of 3.20%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% Takeda Pharmaceutical 3.20%10.50%5.10% Do institutionals and insiders believe in RDY or TAK? 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate RDY or TAK? Dr. Reddy's Laboratories currently has a consensus target price of $16.95, indicating a potential upside of 22.69%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, RDY or TAK? Dr. Reddy's Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Which has better earnings and valuation, RDY or TAK? Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.81B3.03$663M$0.6620.93Takeda Pharmaceutical$30.09B1.53$712.33M$0.3048.20 Does the media favor RDY or TAK? In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 5 mentions for Dr. Reddy's Laboratories and 4 mentions for Takeda Pharmaceutical. Dr. Reddy's Laboratories' average media sentiment score of 1.15 beat Takeda Pharmaceutical's score of 1.06 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDr. Reddy's Laboratories beats Takeda Pharmaceutical on 13 of the 18 factors compared between the two stocks. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$11.35B$3.79B$5.46B$20.63BDividend Yield0.53%1.25%4.61%3.67%P/E Ratio20.939.7729.9528.40Price / Sales3.0312.31448.6455.93Price / Cash13.176.4936.4223.21Price / Book2.804.648.184.33Net Income$663M-$109.62M$3.26B$996.14M7 Day Performance-0.97%7.20%6.12%1.97%1 Month Performance-6.34%8.12%0.94%-0.84%1 Year Performance-17.64%41.11%28.86%14.34% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories2.3853 of 5 stars$13.82+1.6%$16.95+22.7%-17.7%$11.35B$3.81B20.9327,811News CoveragePositive NewsTAKTakeda Pharmaceutical2.5554 of 5 stars$14.27+0.7%N/A+4.3%$45.06B$30.09B47.5547,455Positive NewsARGXargenex4.1164 of 5 stars$690.32+2.5%$746.81+8.2%+26.0%$41.24B$2.25B35.401,599News CoveragePositive NewsONCBeOne Medicines1.3125 of 5 stars$304.30+1.8%$327.56+7.6%N/A$32.77B$3.81B-81.8011,000News CoverageEarnings ReportAnalyst ForecastInsider TradeBNTXBioNTech1.974 of 5 stars$110.03+2.5%$136.58+24.1%+38.7%$25.80B$2.98B-32.366,772Trending NewsEarnings ReportAnalyst ForecastINSMInsmed3.8651 of 5 stars$111.24+2.3%$109.20-1.8%+52.6%$20.62B$363.71M-18.701,271Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics2.0163 of 5 stars$29.32+8.3%$34.67+18.2%+179.9%$20.10B$700K-86.23110Upcoming EarningsOptions VolumeTEVATeva Pharmaceutical Industries2.9415 of 5 stars$15.70+2.1%$24.71+57.4%-4.7%$17.64B$16.54B-98.1336,830Insider TradeGMABGenmab A/S3.7092 of 5 stars$21.98+0.9%$37.80+72.0%-20.8%$13.97B$3.12B12.492,682Trending NewsEarnings ReportUpcoming EarningsShort Interest ↑Analyst RevisionQGENQiagen3.5675 of 5 stars$50.27+0.7%$49.40-1.7%+8.5%$11.10B$1.98B126.045,765News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMRNAModerna4.3307 of 5 stars$27.64+0.1%$45.61+65.0%-69.0%$10.68B$3.24B-3.675,800Earnings ReportAnalyst Revision Related Companies and Tools Related Companies Takeda Pharmaceutical Alternatives argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Insmed Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Qiagen Alternatives Moderna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDY Stock Alerts